4D pharma files Registration Statement on Form F-4 with U.S. Securities and Exchange Commission
4d Pharma PLC (DDDD.L) Longevity extends Business Combination deadline
Longevity receives shareholder approval to extend business combination deadline
4d Pharma PLC (DDDD.L) Proposed Merger & Intention to seek NASDAQ Listing
Leeds, UK – 22 October 2020, – 4D pharma plc (AIM: DDDD) (“4D” or the “Company”), a pharmaceutical company leading the development of Live Biotherapeutic Products (“LBPs”), and Longevity Acquisition